ReviewAntiviral research2014
Treatment of norovirus infections: moving antivirals from the bench to the bedside.
Review in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Disease burden of norovirus-associated diarrhea among children under 5 years old in China: a meta-analysis.BMC infectious diseases · 2025Pooled it
- Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach.Osong public health and research perspectives · 2025Article
- Presentation, management, and outcomes of norovirus in adult and pediatric solid organ and hematopoietic stem cell transplant recipients: A multicenter, retrospective study.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.NPJ vaccines · 2024Review
- Navigating Viral Gastroenteritis: Epidemiological Trends, Pathogen Analysis, and Histopathological Findings.Cureus · 2024Article
- Praemonitus praemunitus: can we forecast and prepare for future viral disease outbreaks?FEMS microbiology reviews · 2023Review
- Review
- Ultrasensitive and visual detection of human norovirus genotype GII.4 or GII.17 using CRISPR-Cas12a assay.Virology journal · 2022Article
- Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study.Frontiers in chemistry · 2022Article
- The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.Infectious disease reports · 2021Article
- Norovirus in Cancer Patients: A Review.Open forum infectious diseases · 2021Review
- Clinical characteristics, risk factors and outcome of severe Norovirus infection in kidney transplant patients: a case-control study.BMC infectious diseases · 2021Article
- Mixed Aetiology of Diarrhoea in Infants Attending Clinics in the North-West Province of South Africa: Potential for Sub-Optimal Treatment.Pathogens (Basel, Switzerland) · 2020Article
- Quantifying the roles of vomiting, diarrhea, and residents vs. staff in norovirus transmission in U.S. nursing home outbreaks.PLoS computational biology · 2020Article
- Norovirus Vaccine: Priorities for Future Research and Development.Frontiers in immunology · 2020Review
- A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase.Scientific reports · 2019Article
- Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.Proteins · 2019Article
- A Secreted Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis.Cell host & microbe · 2019Article
- The Adenosine Analogue NITD008 has Potent Antiviral Activity against Human and Animal Caliciviruses.Viruses · 2019Article
- In silico screening for human norovirus antivirals reveals a novel non-nucleoside inhibitor of the viral polymerase.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Noroviruses (NV) are the most common cause of acute gastrointestinal illness in the United States and worldwide. The development of specific antiviral countermeasures has lagged behind that of other viral pathogens, primarily because norovirus disease has been perceived as brief and self-limiting and robust assays suitable for drug discovery have been lacking. The increasing recognition that NV illness can be life-threatening, especially in immunocompromised patients who often require prolonged hospitalization and intensive supportive care, has stimulated new research to develop an effective antiviral therapy. Here, we propose a path forward for evaluating drug therapy in norovirus-infected immunocompromised individuals, a population at high risk for serious and prolonged illness. The clinical and laboratory features of norovirus illness in immunocompromised patients are reviewed, and potential markers of drug efficacy are defined. We discuss the potential design of clinical trials in these patients and how an antiviral therapy that proves effective in immunocompromised patients might also be used in the setting of acute outbreaks, especially in confined settings such as nursing homes, to block the spread of infection and reduce the severity of illness. We conclude by reviewing the current status of approved and experimental compounds that might be evaluated in a hospital setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.